全文获取类型
收费全文 | 11990篇 |
免费 | 643篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 236篇 |
儿科学 | 381篇 |
妇产科学 | 217篇 |
基础医学 | 1427篇 |
口腔科学 | 337篇 |
临床医学 | 768篇 |
内科学 | 3028篇 |
皮肤病学 | 362篇 |
神经病学 | 755篇 |
特种医学 | 248篇 |
外国民族医学 | 1篇 |
外科学 | 1853篇 |
综合类 | 132篇 |
一般理论 | 5篇 |
预防医学 | 839篇 |
眼科学 | 306篇 |
药学 | 872篇 |
中国医学 | 52篇 |
肿瘤学 | 854篇 |
出版年
2023年 | 72篇 |
2022年 | 119篇 |
2021年 | 338篇 |
2020年 | 181篇 |
2019年 | 331篇 |
2018年 | 497篇 |
2017年 | 285篇 |
2016年 | 287篇 |
2015年 | 295篇 |
2014年 | 407篇 |
2013年 | 540篇 |
2012年 | 881篇 |
2011年 | 957篇 |
2010年 | 454篇 |
2009年 | 384篇 |
2008年 | 788篇 |
2007年 | 775篇 |
2006年 | 783篇 |
2005年 | 722篇 |
2004年 | 655篇 |
2003年 | 589篇 |
2002年 | 548篇 |
2001年 | 191篇 |
2000年 | 207篇 |
1999年 | 196篇 |
1998年 | 65篇 |
1997年 | 47篇 |
1996年 | 56篇 |
1995年 | 49篇 |
1994年 | 39篇 |
1993年 | 26篇 |
1992年 | 67篇 |
1991年 | 58篇 |
1990年 | 60篇 |
1989年 | 55篇 |
1988年 | 45篇 |
1987年 | 60篇 |
1986年 | 52篇 |
1985年 | 47篇 |
1984年 | 38篇 |
1983年 | 45篇 |
1982年 | 31篇 |
1981年 | 27篇 |
1980年 | 22篇 |
1979年 | 33篇 |
1978年 | 22篇 |
1977年 | 20篇 |
1974年 | 34篇 |
1973年 | 19篇 |
1971年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
A Ram Hong Jung Hee Kim Seung Shin Park Sung Hye Kong Hyung Jin Choi Yong Hwy Kim Chan Soo Shin 《Journal of Korean Neurosurgical Society》2022,65(3):439
ObjectiveCraniopharyngiomas (CPs) are associated with hypothalamic damage that causes hypothalamic obesity, however, the mechanisms underlying CP-related postoperative weight gain remain debatable. This study aimed to elucidate whether the major determinant of postoperative weight gain in patients with CP is hypothalamic injury or steroid replacement therapy. MethodsWe included 48 adult patients with CP (age ≥18 years) who underwent transsphenoidal surgery between 2010 and 2018 in a single tertiary center, and whose body weight was measured pre- and postoperatively (<120 days after the surgery). We recruited 144 age- and body mass index-matched patients with non-functioning pituitary adenoma (NFPA) as controls. ResultsPatients with CP experienced greater postoperative weight gain than patients with NFPA (3.0±5.1 vs. 0.1±3.6 kg, p<0.001). The prevalence of postoperative steroid use was significantly higher in patients with CP than in those with NFPA (89.6% vs. 34.0%, p<0.001). Steroid replacement therapy and CP were associated with postoperative weight gain after adjusting for covariates in overall patients (p=0.032 and 0.007, respectively). In subgroup analysis with postoperative steroid users, weight gain was significantly greater in patients with CP (n=43, 0.96±0.25 kg/month) than in patients with NFPA (n=49, 0.26±0.23 kg/month) even after adjusting for the daily steroid dose (p=0.048). ConclusionPatients with CP experience greater postoperative weight gain than those with NFPA. Hypothalamic damage itself as well as steroid replacement may contribute to the postoperative weight gain in patients with CP. 相似文献
82.
Bayés B Lauzurica R Granada ML Serra A Bonet J Fontseré N Salinas I Romero R 《Transplantation》2004,78(1):26-30
BACKGROUND: New-onset diabetes mellitus after transplantation (NODAT) is a severe complication of kidney transplantation (KTx) with negative effects upon patient and graft survival. Several risk factors for NODAT have been described; however, the search for an early predictive marker is ongoing. It has recently been demonstrated that high concentrations of adiponectin (APN), which is an adipocyte-derived peptide with antiinflammatory and insulin-sensitizing properties, protect against future development of type 2 diabetes in healthy individuals. The purpose of this report was to study pretransplant insulin resistance and analyze pretransplant serum leptin and APN levels as independent risk factors for the development of NODAT. METHODS: A total of 68 KTx patients were studied [mean age, 48 +/- 11 years; 70% males; body mass index (BMI), 25 +/- 3 kg/m]; 31 KTx patients with NODAT and 37 KTx patients without NODAT (non-NODAT) with similar age, sex, BMI, immunosuppression, and posttransplant time were studied. All patients received prednisone and calcineurin inhibitors (75% tacrolimus and 25% cyclosporine A), and 76% of patients received mycophenolate mofetil. Family history of diabetes mellitus was recorded. Pretransplant homeostasis model assessment for insulin resistance (HOMA-IR) index was calculated from fasting plasma glucose and insulin. Pretransplant serum leptin and APN levels were determined by radioimmunoassay. RESULTS: NODAT patients showed higher pretransplant plasma insulin concentrations [NODAT, 13.4 (11-22.7) microIU/mL; non-NODAT, 10.05 (7.45-18.4) microIU/mL; P=0.049], HOMA-IR index [NODAT, 4.18 (2.49-5.75); non-NODAT, 2.63 (1.52-4.68); P=0.043], and lower pretransplant serum APN concentration [NODAT, 8.78 (7.2-11.38) microg/mL; non-NODAT, 11.4 (8.56-15.27) microg/mL, P=0.012]. Inverse correlations between APN and BMI (r=-0.33; P=0.014) and APN and HOMA-IR index (r=-0.39; P=0.002) and between APN and NODAT (r=-0.31; P=0.011) were observed. Multiple logistic regression analysis showed the patients with lower pretransplant APN concentrations to be those at greater risk of developing NODAT [Odds Ratio=0.832 (0.71-0.96); P=0.01]. CONCLUSION: Pretransplant serum APN concentration is an independent predictive factor for NODAT development in kidney-transplanted patients. 相似文献
83.
V. Escudero-Ortiz A. Ramón-López M.a J. Duart J.J. Pérez-Ruixo B. Valenzuela 《Farmacia hospitalaria》2012,36(4):282-291
ObjectiveTo develop and internally validate a population pharmacokinetic model for doxorubicin and to evaluate its predictive performance for dose individualization in cancer patients.MethodsDoxorubicin plasma concentrations were determined in thirty-three cancer patients treated with intravenous doxorubicin. A three-compartment pharmacokinetic model was implemented in the NONMEN VI programme to determine the doxorubicin pharmacokinetic parameters. The identifiability of the parameters was assessed by parametric bootstrap and model validation was performed using nonparametric bootstrap, visual predictive check, and numerical predictive check. The final model‘s predictive performance was evaluated in terms of accuracy and precision of plasma concentration predictions during the first and second cycles of chemotherapy.ResultsDoxorubicin clearance was 58.8L/h, with interpatient variability of 29.2% and intrapatient variability of 18.9%. The estimated volume of distribution at steady state was 2294L, with inter-and intrapatient variability of 7.3% and 26.1%, respectively. Internal validation confirmed that the population pharmacokinetic model is appropriate to describe the time course of the doxorubicin plasma concentrations and its variability in this population. The accuracy and precision of an a posteriori prediction of doxorubicin plasma concentrations improved by 63% and 41% compared to the a priori prediction.ConclusionThe Bayesian population pharmacokinetic model characterised the time course of doxorubicine plasma concentrations and can be accurately and precisely used to optimise doxorubicine dosing regimens in cancer patients. 相似文献
84.
A. Ramón-López V. Escudero-Ortiz V. Carbonell J.J. Pérez-Ruixo B. Valenzuela 《Farmacia hospitalaria》2012,36(5):392-402
ObjectiveTo develop and internally validate a population pharmacokinetics model for cisplatin and assess its prediction capacity for personalising doses in cancer patients.MethodCisplatin plasma concentrations in forty-six cancer patients were used to determine the pharmacokinetic parameters of a two-compartment pharmacokinetic model implemented in NONMEN VI software. Pharmacokinetic parameter identification capacity was assessed using the parametric bootstrap method and the model was validated using the nonparametric bootstrap method and standardised visual and numerical predictive checks. The final model's prediction capacity was evaluated in terms of accuracy and precision during the first (a priori) and second (a posteriori) chemotherapy cycles.ResultsMean population cisplatin clearance is 1.03 L/h with an interpatient variability of 78.0%. Estimated distribution volume at steady state was 48.3 L, with inter- and intrapatient variabilities of 31,3% and 11,7%, respectively. Internal validation confirmed that the population pharmacokinetics model is appropriate to describe changes over time in cisplatin plasma concentrations, as well as its variability in the study population. The accuracy and precision of a posteriori prediction of cisplatin concentrations improved by 21% and 54% compared to a priori prediction.ConclusionThe population pharmacokinetic model developed adequately described the changes in cisplatin plasma concentrations in cancer patients and can be used to optimise cisplatin dosing regimes accurately and precisely. 相似文献
85.
Análisis y minimización del riesgo de rotura de stock aplicado a la gestión en farmacia hospitalaria
José María Maestre Torreblanca Beatriz Isla Tejera María Isabel Fernández García José Ramón del Prado Llergo Teodoro Álamo Cantarero Eduardo Fernández Camacho 《Farmacia hospitalaria》2012,36(3):130-134
ObjectiveTo determine how many dispensary drugs should be in the safety stock in a tertiary hospital in accordance with the risk level and the number of days that the hospital is able to withstand a stockout.MethodsWe statistically analysed the infliximab order recorded over a period of 120 days. This drug is relevant for this study as it is costly and is immediately supplied to the clinic. Using the data records for purchasing and dispensing in our department, we created a table to compare the level of risk assumed with the number of units in stock and the number of days that the safety stock should last. In addition, we calculated how much stock there should be in accordance with different heuristic rules used by pharmacy departments.ResultsIn the period being studied, the daily order was 11.4 ± 14.8 units of infliximab. Using the methodology proposed, we discovered that there should be 79 units in the safety stock. Other hospital rules determine values of 47 and 119 units.ConclusionsThe method proposed allows us to discover the risk level that is assumed when selecting the safety stock. Therefore, we are able to design a safety stock policy consistent with the risk level adopted. Under certain assumptions the safety stock quota provided by this method could be reduced. Lastly, there is a notable difference between the safety stock values suggested by different rules, as it has been shown in this article. 相似文献
86.
María del Carmen Robles-Ramírez Eva Ramón-Gallegos Francisco J. Reyes-Duarte Rosalva Mora-Escobedo 《Nutrition and cancer》2013,65(8):1261-1268
Previous studies showed that germination could improve the antiproliferative effect of soy protein on cervical cancer cells and that a peptide fraction (MAPF) from germinated soybeans decreases the expression of PTTG1 and TOP2A (2 genes considered as therapeutic targets) causing apoptosis of cancer cells. The aim of this work was to study the effect of feeding germinated soybean protein diets on the tumor growth in nude mice inoculated with cervical cancer cells and identify the bioactive component. Mice were randomly assigned to 1 of the 6 dietary groups based in AIN-93G formulation with 6 protein sources: casein, ungerminated soy protein (SP), and SP from 2 and 6 days of germination, with and without ethanol-soluble phytochemicals (ESPC). Compared with casein-fed controls, the tumor volumes after 5 wk were reduced by 44.6% by ungerminated SP, 98.9% by 2-day-germinated SP, 97.7% by 2-day-germinated SP without ESPC, 94.7% by 6-day-germinated SP, and 92.7% by 6-day-germinated SP without ESPC (P < 0.05). Liquid chromatography coupled with tandem mass spectrometry analysis of MAPF showed that the bioactive peptide might be the leginsulin, a peptide involved in signal transduction of soybean cells. Germination is a simple procedure that could help to increase the anticancer activity of soy protein probably through generation of biologically active peptides. 相似文献
87.
M.T. Vicente-Herrero M.J. Terradillos-García M.V. Ramírez-Iñiguez-de la Torre L.M. Capdevila-García A.A. López-González 《Revista de gastroenterologia de Mexico》2013,78(2):75-81
BackgroundColorectal cancer is one of the most frequent cancers in both sexes and the most frequent in the developed countries, if men and women are considered together as a group. It has an important associated morbidity and mortality in all countries and constitutes a public health problem with a high direct and indirect economic cost. The number of workdays lost due to temporary disability (TD) is one of the quantifiable references of these indirect costs.AimsTo determine the indirect cost associated with TD due to colorectal cancer in Spain during the year 2011, a cost that aids in the prevention cost/benefit estimation.MethodsThe number of TD processes, the number of workdays lost due to TD, and the mean duration of those processes, based on the CIE 9-MC codes related to this pathology, as well as the calculated cost, using the Spanish minimum wage as a reference, during the period of January to December 2011, were all reviewed.ResultsColorectal cancer in Spain during 2011 represented 1,046 TD processes, 202,784 workdays lost, and a mean process duration of 194 days/year. The resulting cost of the pathology due to TD was 4,335,521.92 euros.ConclusionsThese results are beneficial for evaluating the usefulness of implementing public health support strategies for a greater reduction in colorectal cancer prevalence and mortality, and an improvement in quality of life of the affected individuals and their families, together with an economic savings resulting from a reduction in TD as a consequence of this disease. 相似文献
88.
89.
90.